Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

Nature Medicine

Volumn 10, Issue 1, 2004, Pages 48-54

  Wang, Tianhong ^a   Niu, Guilian ^b   Kortylewski, Marcin ^b   Burdelya, Lyudmila ^b   Shain, Kenneth ^b   Zhang, Shumin ^b   Bhattacharya, Raka ^b   Gabrilovich, Dmitry ^b   Heller, Richard ^b   Coppola, Domenico ^b   Dalton, William ^b   Jove, Richard ^b   Pardoll, Drew ^a   Yu, Hua ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN; DNA BINDING PROTEIN; STAT3 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL FUNCTION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; INFLAMMATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNOLOGY; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; GEL MOBILITY SHIFT ASSAY; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, NATURAL; MELANOMA, EXPERIMENTAL; MICE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 11144357779     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm976     Document Type: Article

References (38)

1. Kaplan, D.H. et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-7561 (1998).
2. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
3. Fuchs, E.J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280 (1996).
4. Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525-531 (1998).
5. Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351-358 (2002).
6. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
7. Gabrilovich, D.I. et al, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103 (1996).
8. Sombroek, C.C. et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168, 4333-4343 (2002).
9. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49 (1999).
10. Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425-436 (2003).
11. Bromberg, J.F. et al. Stat3 as an oncogene. Cell 98, 295-303 (1999).
12. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115 (1999).
13. Bowman, T. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98, 7319-7324 (2001).
14. Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008 (2002).
15. Bowman, T., Garcia, R., Turkson, J. & Jove, R. STATs in oncogenesis. Oncogene 19, 2474-2488 (2000).
16. Niu, G. et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59, 5059-5063 (1999).
17. Niu, G. et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 61, 3276-3280 (2001).
18. Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13 (1989).
19. Fearon, D.T. & Locksley, R.M. The instructive role of innate immunity in the acquired immune response. Science 272, 50-54 (1996).
20. Medzhitov, R. & Janeway, J., C.A. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9, 4-9 (1997).
21. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
22. Mellman, I. & Steinman, R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
23. Bloom, M.B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453-459 (1997).
24. Slansky, J.E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529-538 (2000).
25. McLemore, M.L. et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14, 193-204 (2001).
26. Brossart, P. et al. Tumor necrosis factor α and CD40 ligand antagonize the inhibitory effect of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60, 4485-4492 (2000).
27. Weber-Nordt, R.M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954-27961 (1996).
28. Bartoll, M. et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 17, 1562-1564 (2003).
29. Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. 276, 45443-45455 (2001).
30. Davidson, J.M. Wound repair. in Inflammation (ed. J.L. Gallin) 809-819 (Garland Press, New York, 1992).
31. Sano, S. et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18, 4657-4668 (1999).
32. Urban, J.L., Burton, R.C., Holand, J.M., Kripke, M.L. & Schreiber, H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155, 557-573 (1982).
33. Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052 (1983).
34. Wortzel, R.D., Philipps, C. & Schreiber, H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304, 165-167 (1983).
35. Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature411, 1058-1064 (2001).
36. Lee, C.K. et al. Stat3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17, 63-72 (2002).
37. Turkson, J. et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. 18, 2545-2552 (1998).
38. + cytotoxic T lymphocytes. J. Exp. Med. 191, 541-550 (2000).